Ian Liebling

Ian Liebling

Auto-generated profile, based on publicly available information

Ian Liebling

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2024 in Cancer Discovery
Verified
Journal Article
Closed access
KLKatherine E. Lindblad
Katherine E. Lindblad
Romain DonneRomain Donne
Romain Donne
ILIan Liebling
Ian Liebling
MBMarina Barcena-Varela
Marina Barcena-Varela
ALAnthony Lozano
Anthony Lozano
ALAmaia Lujambio
Amaia Lujambio
Hepatocellular carcinoma presents strong sexual dimorphism, being two to three times more frequent in males than in females; however, the role of sex in response to immunotherapies in HCC remains unknown. We demonstrate that NOTCH1, an understudied oncogene in HCC, elicits sexually dimorphic antitumor immunity and response to FDA-approved immunotherapies. Surprisingly, males harboring NOTCH1-driven tumors displayed enhanced antitumor immune responses, which, in mice, were mediated by dendritic and T cells. Conversely, females harboring NOTCH1-driven tumors presented immune evasion and resistance to immunotherapies through a defect in dendritic cell (DC)–mediated priming and activation of CD8+ T cells in mice, which was restored therapeutically with CD40 agonism. Mechanistically, the sexually dimorphic immunity was mediated by genes in the sex chromosomes but not by sex hormones. Together, our study unravels an unexpected association between NOTCH1 and sex in cancer immunity and highlights the potential of restoring the DC−CD8+ T-cell axis with CD40 agonism to improve outcomes. Significance: Although HCC presents strong sexual dimorphism, the role of sex in response to immunotherapies remains elusive. With a novel HCC mouse model and validation in patients with HCC, we demonstrate that NOTCH1 disrupts antitumor immunity specifically in females through a mechanism mediated by sex chromosome genes, which is reversed with CD40 agonism. See related commentary by Zhu and Koltsova, p. 452

12 December 2025 in bioRxiv
Verified
Preprint
Open access
MBMarina Barcena-Varela
Marina Barcena-Varela
JSJoan Shang
Joan Shang
IMIlaria Mogno
Ilaria Mogno
ALAnthony Lozano
Anthony Lozano
ILIan Liebling
Ian Liebling
ALAmaia Lujambio
Amaia Lujambio
Background and Aims: Growing evidence highlight the critical role of the gut microbiome in tumorigenesis and response to immunotherapies. However, the impact of gut microbes on hepatocellular carcinoma (HCC) progression and response to immune-checkpoint blockade (ICB) remains unclear due to the lack of combined preclinical and clinical studies. Approach & Results: We performed 16S rRNA of cross-cohort stool samples from 10 HCC responders (R) and 40 non-responders (NR) to ICB at baseline and on-treatment time-points. We identified an enrichment of Bacteroidetes in NR. To study the role of the microbiome in the cancer immune response, we generated an immunogenic mouse model of HCC via hydrodynamic tail-vein injection (HDTVI) of DNA plasmids mimicking common HCC alterations and immunogenicity by expressing model antigens (MYC-lucOS;CTNNB1 tumors). We found that antibiotic (ABX)-induced dysbiosis promoted a pro-tumorigenic effect in the MYC-lucOS;CTNNB1 HCC model by the expansion of a specific Bacteroidetes, Parabacteroides distasonis. Colonization of mice carrying MYC-lucOS;CTNNB1 HCCs with Parabacteroides distasonis confirmed its pro-tumorigenic effect in vivo. Furthermore, we explored the effects of colonizing with microbiotas from patients and showed that microbiota from a NR donor enriched in Bacteroidetes promoted faster tumorigenesis than microbiota from a R donor with reduced Bacteroidetes. We isolated 6 Bacteroidetes species from the NR donor, cultured them, and used them as a cocktail to colonize mice; similarly, mice transplanted with this cocktail showed increased tumorigenesis and reduced survival. Conclusions: This study identified Bacteroidetes enrichment as a potential biomarker of ICB resistance in HCC and, by using immunogenic mouse models, established that Bacteroidetes abundance influences tumor development.

17 June 2026
Verified
Other
Open access
KLKatherine E. Lindblad
Katherine E. Lindblad
Romain DonneRomain Donne
Romain Donne
ILIan Liebling
Ian Liebling
MBMarina Barcena-Varela
Marina Barcena-Varela
ALAnthony Lozano
Anthony Lozano
ALAmaia Lujambio
Amaia Lujambio
Hepatocellular carcinoma presents strong sexual dimorphism, being two to three times more frequent in males than in females; however, the role of sex in response to immunotherapies in HCC remains unknown. We demonstrate that NOTCH1, an understudied oncogene in HCC, elicits sexually dimorphic antitumor immunity and response to FDA-approved immunotherapies. Surprisingly, males harboring NOTCH1-driven tumors displayed enhanced antitumor immune responses, which, in mice, were mediated by dendritic and T cells. Conversely, females harboring NOTCH1-driven tumors presented immune evasion and resistance to immunotherapies through a defect in dendritic cell (DC)–mediated priming and activation of CD8+ T cells in mice, which was restored therapeutically with CD40 agonism. Mechanistically, the sexually dimorphic immunity was mediated by genes in the sex chromosomes but not by sex hormones. Together, our study unravels an unexpected association between NOTCH1 and sex in cancer immunity and highlights the potential of restoring the DC−CD8+ T-cell axis with CD40 agonism to improve outcomes.Significance:Although HCC presents strong sexual dimorphism, the role of sex in response to immunotherapies remains elusive. With a novel HCC mouse model and validation in patients with HCC, we demonstrate that NOTCH1 disrupts antitumor immunity specifically in females through a mechanism mediated by sex chromosome genes, which is reversed with CD40 agonism.See related commentary by Zhu and Koltsova, p. 452

17 June 2026
Verified
Other
Open access
PDF file
KLKatherine E. Lindblad
Katherine E. Lindblad
Romain DonneRomain Donne
Romain Donne
ILIan Liebling
Ian Liebling
MBMarina Barcena-Varela
Marina Barcena-Varela
ALAnthony Lozano
Anthony Lozano
ALAmaia Lujambio
Amaia Lujambio
NOTCH1-driven tumors in females lead to impaired CD8+ T cell priming and activation


3 March 2025
Verified
Other
Open access
KLKatherine E. Lindblad
Katherine E. Lindblad
Romain DonneRomain Donne
Romain Donne
ILIan Liebling
Ian Liebling
MBMarina Barcena-Varela
Marina Barcena-Varela
ALAnthony Lozano
Anthony Lozano
ALAmaia Lujambio
Amaia Lujambio
Sex-dependent immune responses in NOTCH1-driven liver tumors